Living with Sickle Cell Disease is a challenge itself, however SC Warriors encounter other issues that can lead to death. We aim to provide all kinds of resources to our clients to be able to live their best life. In this session, we will address respiratory diseases that can become life-threatening complications in people living with SCD that can result in lung injury, breathing difficulty, and low oxygen to the rest of the body.
CMEs and Enduring Materials are offered.
The objectives addressed:
- Who is at risk for respiratory disease in sickle cell disease?
- When or should there be screening for respiratory disease?
- What is the natural history of respiratory disease?
- What are the treatments available for respiratory disease?
Meet our Subject-Matter Expert | Elizabeth Klings, M.D.
Dr. Klings is an Associate Professor in the Department of Medicine. She attends the Medical Intensive Care Unit and on the Pulmonary Consultation Service at Boston Medical Center. Additionally, she has a clinic in the Pulmonary Hypertension Center at Boston Medical Center where she is involved in the diagnosis, evaluation and treatment of patients with pulmonary hypertension ( Pulmonary Hypertension Center ). She has special interest in the management of patients with chronic dyspnea and is the former Medical Director of the Pulmonary Rehabilitation Program.
Dr. Klings’ research since fellowship has focused on pathogenesis of pulmonary vascular complications of sickle cell disease. She is a Principal Investigator in the Pulmonary Center collaborating with investigators both at Boston University and throughout the United States. She has clinically phenotyped over 200 adults with sickle cell disease being treated at Boston Medical Center and has utilized genomic and proteomic approaches to understand the pathogenesis for pulmonary vascular disease in this population. Her current research interests surround understanding the role of sleep-disordered breathing, chronic intermittent hypoxia and thrombosis as pulmonary vascular modulators in sickle cell disease. Known internationally as a leader in the care and treatment of patients with sickle cell disease and pulmonary hypertension, she headed a committee of 25 hematologists, pulmonologists and cardiologists to develop clinical guidelines sponsored by the American Thoracic Society for the care and treatment of these patients, which was published in 2014. In 2017, she co-chaired a workshop of 32 hematologists and pulmonologists to define the necessary clinical and research directions in sickle cell lung disease.
Meet our Moderator | Keith Quirolo, M.D.
Dr. Quirolo has a degree in biology from San Francisco State University, a degree in nursing from the UCSF School of Nursing, he received his MD degree from Case Western Reserve School of Medicine and completed a Fellowship in Transfusion Medicine at UCSF. Dr. Quirolo practiced as an RN for approximately 10 years in pediatric oncology and intensive care in the Bay Area and during medical school at Rainbow Baby and Children’s Hospital in Cleveland Ohio. After his pediatric residency, he entered private pediatric practice in Berkeley for about 10 years. He moved to the sickle cell program at the then-Children’s Hospital Oakland in 1995. He served as the Director of Pediatric Sickle Cell Program at UCSF Benioff Children’s Hospital in Oakland for 20 years. Keith served on the FDA Blood Advisory Committee for two years, and he initiated and directed the Clinical Apheresis Program at UCSF Benioff Children’s Hospital for 17 years. Keith has left the practice of medicine and is currently consulting for community-based organizations and other advocacy projects.